Pharmacokinetics, Efficacy, Gametocyte Carriage, Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment in Pregnant Women

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The main purpose of this study is to compare the drug levels of sulfadoxine-pyrimethamine found when given to pregnant women for the prevention of malaria to those found in pregnant women given the same drug with artesunate for the treatment of malaria, and also with those drug levels found in non-pregnant women in other malaria treatment studies.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Professor Karen I Barnes
• Collaborators: Global Fund; Medical Research Council, South Africa
• Treatments: Fanasil, pyrimethamine drug combination; Pyrimethamine; Sulfadoxine

Criteria

Inclusion Criteria:

• Pregnant female, older than 18 years, > 35kg.

• Gestational age > 16 weeks (fundal height > 16cm) and below 36 weeks gestation.

• Documented informed consent.

• Lives close enough to the study site for reliable follow up and is willing to attend ANC and follow-up visits regularly.

Exclusion Criteria:

• Diagnoses of uncomplicated acute P. falciparum malaria parasitaemia

• Has received anti-malarial treatment in the past 7 days and/or sulfadoxine-pyrimethamine in the past 28 days.

• Known hepatic or renal impairment

• Has received chloramphenicol, cotrimoxazole or tetracyclines (including doxycycline) in the past 7 days or is likely to require these during the study period.

• History of G6PD deficiency.

• Has a history of allergy to any of the study drugs (including other sulphonamides e.g. cotrimoxazole).

• Serious underlying disease that in the opinion of the clinic team and/or Principal Investigator would make the patient unsuitable for the study in terms of their safety or study analysis.

• Imminent delivery expected.

• Prior inclusion in this study.